Anti-CD79a [JCB117] rAb

Tool Details

*FOR RESEARCH USE ONLY

• Name: Anti-CD79a [JCB117] rAb
• Alternate name: CD79a Molecule; Membrane-Bound Immunoglobulin-Associated Protein; Surface IgM-Associated Protein; MB-1 Membrane Glycoprotein; Ig-Alpha; IGA; CD79a Antigen; MB1
• Clone: JCB117
• Tool sub type: Primary antibody
• Class: Recombinant
• Conjugation: Unconjugated
• Reactivity: Human
• Host: Mouse
• Description: The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling. CD79a is widely used as an adjunct to CD20 as a biomarker for normal and neoplastic B-cells in tissues sections.
• Immunogen: Synthetic peptide of 14 amino acids representing residues 202-216 of the human mb-1 cDNA sequence
• Isotype: IgG1

Target Details

• Target: CD79a
• Target background: The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling. CD79a is widely used as an adjunct to CD20 as a biomarker for normal and neoplastic B-cells in tissues sections.

Handling

• Format: Liquid
• Unit size: 100 ug
• Shipping conditions: Shipping at 4° C

References

• Arana et al. 2016. J Clin Pathol. :. PMID: 27484914.
• Boudova et al. 2005. Am J Dermatopathol. 27(5):375-86. PMID: 16148405.
• Boudova et al. 2006. J Cutan Pathol. 33(8):584-9. PMID: 16919035.
• CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.
• Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.
• Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients.
• Delli et al. 2016. Ann Rheum Dis. :. PMID: 26757748.
• HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens.
• Higashi et al. 2015. Leuk Lymphoma. :1-6. PMID: 25860238.
• Korkolopoulou et al. 1994. Histopathology. 24(6):511-5. PMID: 7520411.
• Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
• Mason et al. 1995. Blood. 86(4):1453-9. PMID: 7632952.
• Pilozzi et al. 1998. J Pathol. 186(2):140-3. PMID: 9924428.
• Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman.
• Radaev et al. 2010. Structure. 18(8):934-43. PMID: 20696394.
• Structural and Fn studies of Igalphabeta and its assembly with the B cell antigen receptor.
• The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease.
• Towards personalised treatment in primary Sjgren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.